Gurumurthy, Prema <br/><br/>
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Nov 2004 
 - 4473-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0066-4804 
<br/><br/><label>Standard No.: </label>10.1128/AAC.48.11.4473-4475.2004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylation<br/>Adult<br/>Antibiotics, Antitubercular--pharmacokinetics<br/>Antitubercular Agents--pharmacokinetics<br/>Biological Availability<br/>Ethambutol--pharmacokinetics<br/>Feces--microbiology<br/>Female<br/>HIV Infections--complications<br/>Humans<br/>Intestinal Absorption<br/>Isoniazid--pharmacokinetics<br/>Male<br/>Middle Aged<br/>Phenotype<br/>Pyrazinamide--pharmacokinetics<br/>Rifampin--pharmacokinetics<br/>Tuberculosis--complications